Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda

This study has been completed.
Sponsor:
Collaborators:
University of Washington
Johns Hopkins University
Translational Genomics Research Institute
Information provided by (Responsible Party):
Steven Reynolds, National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00405821
First received: November 29, 2006
Last updated: August 28, 2012
Last verified: August 2012
Results First Received: July 18, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
Herpes Genitalis
Interventions: Drug: Acyclovir
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
440 HIV+ subjects recruited in rural Rakai, Uganda within the Rakai Health Sciences Program mobile medical clinic during May 2007 thru November 2008

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All subjects were randomized to study arm, and initiated study treatment at the time of enrollment.

Reporting Groups
  Description
Acyclovir 400mg Tablet Twice Daily No text entered.
Placebo Tablet Twice Daily No text entered.

Participant Flow:   Overall Study
    Acyclovir 400mg Tablet Twice Daily   Placebo Tablet Twice Daily
STARTED   220   220 
COMPLETED   198   198 
NOT COMPLETED   22   22 
Death                5                7 
Lost to Follow-up                7                7 
Protocol Violation                1                0 
initiated ART                9                8 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Acyclovir 400mg Tablet Twice Daily No text entered.
Placebo Tablet Twice Daily No text entered.
Total Total of all reporting groups

Baseline Measures
   Acyclovir 400mg Tablet Twice Daily   Placebo Tablet Twice Daily   Total 
Overall Participants Analyzed 
[Units: Participants]
 220   220   440 
Age, Customized 
[Units: Participants]
     
20-29 years   46   44   90 
30-39 years   94   93   187 
40-49 years   54   53   107 
50+ years   26   30   56 
Gender 
[Units: Participants]
     
Female   150   161   311 
Male   70   59   129 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis)   [ Time Frame: 2 years ]

2.  Secondary:   Difference in Number of Episodes of Genital Ulcer Disease Between Arms   [ Time Frame: 2 years ]

3.  Secondary:   HIV-1 Viral Load Difference Between Arms   [ Time Frame: baseline, 6 months, 12 months, 18 months, 24 months ]

4.  Secondary:   Toxicity of Acyclovir   [ Time Frame: 2 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes

5.  Secondary:   Adherence to Acyclovir   [ Time Frame: 2 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Virologic and Immunologic Responses to ART in Those Who Progress to CD+4 Less Than 250cells/mL   [ Time Frame: 6 months and 12 moths post ART initiation ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame maximum follow-up time on this study ranged from 24 months to 41 months depending on time of enrollment.
Additional Description No text entered.

Reporting Groups
  Description
Acyclovir 400mg Tablet Twice Daily No text entered.
Placebo Tablet Twice Daily No text entered.

Serious Adverse Events
    Acyclovir 400mg Tablet Twice Daily   Placebo Tablet Twice Daily
Total, serious adverse events     
# participants affected / at risk   75/220 (34.09%)   85/220 (38.64%) 
Blood and lymphatic system disorders     
Anemia †     
# participants affected / at risk   7/220 (3.18%)   13/220 (5.91%) 
# events   9   16 
Gastrointestinal disorders     
Peptic ulcer disease †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
Cholecystitis †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
Hepatotoxicity †     
# participants affected / at risk   0/220 (0.00%)   1/220 (0.45%) 
# events   0   1 
Abdominal pain, unspecified †     
# participants affected / at risk   1/220 (0.45%)   3/220 (1.36%) 
# events   1   3 
General disorders     
Dehydration †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
Febrile Illness, unspecified †     
# participants affected / at risk   5/220 (2.27%)   5/220 (2.27%) 
# events   5   6 
Infections and infestations     
TB Adenitis †     
# participants affected / at risk   1/220 (0.45%)   1/220 (0.45%) 
# events   1   1 
Malaria †     
# participants affected / at risk   26/220 (11.82%)   24/220 (10.91%) 
# events   29   34 
Mastitis †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
skin infection, unspecified †     
# participants affected / at risk   1/220 (0.45%)   1/220 (0.45%) 
# events   1   1 
EENT infection, unspecified †     
# participants affected / at risk   1/220 (0.45%)   1/220 (0.45%) 
# events   1   1 
Bacterial pneumonia †     
# participants affected / at risk   3/220 (1.36%)   2/220 (0.91%) 
# events   3   2 
Pulmonary Tuberculosis †     
# participants affected / at risk   13/220 (5.91%)   13/220 (5.91%) 
# events   13   14 
Extra-pulmonary tuberculosis †     
# participants affected / at risk   2/220 (0.91%)   0/220 (0.00%) 
# events   2   0 
Upper respiratory tract infection †     
# participants affected / at risk   1/220 (0.45%)   1/220 (0.45%) 
# events   1   1 
Lower respiratory tract infection †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
Cryptococcal meningitis †     
# participants affected / at risk   0/220 (0.00%)   1/220 (0.45%) 
# events   0   1 
Esophageal candidiasis †     
# participants affected / at risk   0/220 (0.00%)   1/220 (0.45%) 
# events   0   1 
Gastroenteritis †     
# participants affected / at risk   0/220 (0.00%)   2/220 (0.91%) 
# events   0   2 
Genito-urinary disease (GUD) †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
Cystitis †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
Urinary Tract Infection †     
# participants affected / at risk   2/220 (0.91%)   0/220 (0.00%) 
# events   2   0 
Injury, poisoning and procedural complications     
Trauma to chest †     
# participants affected / at risk   2/220 (0.91%)   0/220 (0.00%) 
# events   2   0 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
Kaposi's sarcoma †     
# participants affected / at risk   1/220 (0.45%)   2/220 (0.91%) 
# events   1   2 
Pregnancy, puerperium and perinatal conditions     
Abortion †     
# participants affected / at risk   2/220 (0.91%)   1/220 (0.45%) 
# events   2   1 
Pregnancy †     
# participants affected / at risk   30/220 (13.64%)   41/220 (18.64%) 
# events   37   52 
Pregnancy complication, unspecified †     
# participants affected / at risk   5/220 (2.27%)   2/220 (0.91%) 
# events   5   2 
Reproductive system and breast disorders     
Pelvic inflammatory disease †     
# participants affected / at risk   1/220 (0.45%)   1/220 (0.45%) 
# events   1   1 
Respiratory, thoracic and mediastinal disorders     
Respiratory complaint, unspecified †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   1   0 
Pleural effusion †     
# participants affected / at risk   1/220 (0.45%)   0/220 (0.00%) 
# events   2   0 
Skin and subcutaneous tissue disorders     
wound, unspecified †     
# participants affected / at risk   1/220 (0.45%)   2/220 (0.91%) 
# events   1   2 
Vascular disorders     
Hypertension †     
# participants affected / at risk   0/220 (0.00%)   1/220 (0.45%) 
# events   0   1 
Events were collected by systematic assessment




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Steven Reynolds
Organization: NIAID
phone: 256-772-220-087
e-mail: sjreynolds@niaid.nih.gov


Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Steven Reynolds, National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00405821     History of Changes
Other Study ID Numbers: 999907032
07-I-N032 ( Other Identifier: NIAID Intramural IRB )
Study First Received: November 29, 2006
Results First Received: July 18, 2012
Last Updated: August 28, 2012
Health Authority: United States: Federal Government
Uganda: Research Ethics Committee
Uganda: National Council for Science and Technology